Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Subscribe To Our Newsletter & Stay Updated